Advertisement

Quality of life in patients with antiphospholipid antibodies differs according to antiphospholipid syndrome damage index (DIAPS)

  • Massimo Radin
    Correspondence
    Corresponding author at: Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences University of Turin and SCDU Nephrology and Dialysis, S. Giovanni Bosco Hospital, Piazza del Donatore di Sangue 3, 10154, Turin, Italy.
    Affiliations
    Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, and SCDU Nephrology and Dialysis, S. Giovanni Bosco Hospital and University of Turin, Turin, Italy
    Search for articles by this author
  • Silvia Grazietta Foddai
    Affiliations
    Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, and SCDU Nephrology and Dialysis, S. Giovanni Bosco Hospital and University of Turin, Turin, Italy
    Search for articles by this author
  • Irene Cecchi
    Affiliations
    Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, and SCDU Nephrology and Dialysis, S. Giovanni Bosco Hospital and University of Turin, Turin, Italy
    Search for articles by this author
  • Dario Roccatello
    Affiliations
    Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, and SCDU Nephrology and Dialysis, S. Giovanni Bosco Hospital and University of Turin, Turin, Italy
    Search for articles by this author
  • Savino Sciascia
    Affiliations
    Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, and SCDU Nephrology and Dialysis, S. Giovanni Bosco Hospital and University of Turin, Turin, Italy
    Search for articles by this author

      Highlights

      • Patients with APS may face permanent damage in various organs.
      • Patients with secondary APS had the highest levels of DIAPS.
      • DIAPS correlated both with risk stratification scores and with QoL questionnaires.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Miyakis S
        • Lockshin MD
        • Atsumi T
        • Branch DW
        • Brey RL
        • Cervera R
        • Derksen RHWM
        • DE Groot PG
        • Koike T
        • Meroni PL
        • Reber G
        • Shoenfeld Y
        • Tincani A
        • Vlachoyiannopoulos PG
        • Krilis SA.
        International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).
        J Thromb Haemost. 2006; 4: 295-306
        • Grika EP
        • Ziakas PD
        • Zintzaras E
        • Moutsopoulos HM
        • Vlachoyiannopoulos PG.
        Morbidity, mortality, and organ damage in patients with antiphospholipid syndrome.
        J Rheumatol J Rheumatol. 2012; 39: 516-523
        • Amigo MC
        • Goycochea-Robles MV.
        • Espinosa-Cuervo G
        • Medina G
        • Barragán-Garfias JA
        • Vargas A
        • Jara LJ.
        Development and initial validation of a damage index (DIAPS) in patients with thrombotic antiphospholipid syndrome (APS).
        Lupus. 2015; 24: 927-934
        • Gladman D
        • Ginzler E
        • Goldsmith C
        • Fortin P
        • Liang M
        • Urowitz M
        • Bacon P
        • Bombardieri S
        • Hanly J
        • Hay E
        • Isenberg D
        • Jones J
        • Kalunian K
        • Maddison P
        • Nived O
        • Petri M
        • Richter M
        • Sanchez-Guerrero J
        • Snaith M
        • Sturfelt G
        • et al.
        The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus.
        Arthritis Rheum. 1996; 39: 363-369
        • Sciascia S
        • Sanna G
        • Murru V
        • Roccatello D
        • Khamashta MA
        • Bertolaccini ML.
        GAPSS: the global anti-phospholipid syndrome score.
        Rheumatology (Oxford). 2013; 52: 1397-1403
        • Ware JE
        • Kosinski M
        • Keller SD
        • Care SM
        • Mar N.
        A 12-item short-form health survey of scales and preliminary construction tests of reliability and validity.
        Construction. 2015; 34: 220-233
        • Cervera R
        • Serrano R
        • Pons-Estel GJ
        • Ceberio-Hualde L
        • Shoenfeld Y
        • De Ramón E
        • Buonaiuto V
        • Jacobsen S
        • Zeher MM
        • Tarr T
        • Tincani A
        • Taglietti M
        • Theodossiades G
        • Nomikou E
        • Galeazzi M
        • Bellisai F
        • Meroni PL
        • Derksen RHWM
        • De Groot PGD
        • Baleva M
        • et al.
        Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients.
        Ann Rheum Dis. 2015;
        • Torricelli AK
        • Ugolini-Lopes MR
        • Bonfá E
        • Andrade D.
        Antiphospholipid syndrome damage index (DIAPS): distinct long-term kinetic in primary antiphospholipid syndrome and antiphospholipid syndrome related to systemic lupus erythematosus.
        Lupus. 2020; 29: 256-262
        • Georgopoulou S
        • Efraimidou S
        • Maclennan SJ
        • Ibrahim F
        • Antiphospholipid Cox T.
        Hughes) syndrome: description of population and health-related quality of life (HRQoL) using the SF-36.
        Lupus. 2015; 24: 174-179
        • Zuily S
        • Rat AC
        • Regnault V
        • Kaminsky P
        • Mismetti P
        • Ninet J
        • Baillet N
        • Magy-Bertrand N
        • Pasquali JL
        • Lambert M
        • Pasquier E
        • Lorcerie B
        • Lecompte T
        • Guillemin F
        • Wahl D.
        Impairment of quality of life in patients with antiphospholipid syndrome.
        Lupus. 2015; 24: 1161-1168